




EGFR Resisters **RESEARCH SUMMIT**

*An Academic Research Summit Focusing on the Advancement of
EGFRm Treatment Paradigms through Meaningful Collaboration
between Physician Scientist Investigators and Patients*

www.ceconcepts.com/egfrsummit

Follow us on Twitter **@EGFRSummit**



The Third Annual EGFR Resisters Research Summit convened virtually on November 11-15, 2021 to ensure the safety of the patients, young investigators, and expert judge mentors during this time of the COVID-19 pandemic.

The 17 Young Investigators and eight Expert Judge Mentors kicked off the meeting with a professional development and mentoring panel focused on real-world topics that impact early career researchers; topics included grant writing, how to approach a career in academic leadership, when to say yes and when to say no, finding mentors, working with cooperative groups, and how to leverage social media. During the Sunday reception, EGFR Resisters

founding members, Ivy Elkins and Jill Feldman, launched this year's EGFR Resisters Summit. The two patients discussed the mission of the EGFR Resisters patient group and the critical need for research advancements in *EGFR* non-small-cell lung cancer (NSCLC), as well as recent breakthroughs and significant obstacles affecting the care of their fellow survivors. A highlight in the Welcome Reception was the EGFR Resisters' work with the International Association for the Study of Lung Cancer (IASLC) in the creation of the IASLC Language Guide (available at: <https://www.iaslc.org/IASLCLanguageGuide>) to promote patient-first language throughout clinical practice and research, which fittingly illustrated the overarching purpose of the EGFR Summit: to advance the *EGFR* treatment paradigm through meaningful collaboration between physician scientist investigators and patients.

Sunday held two Breakout Sessions in which the Young Investigators presented their research to the Expert Judge Mentors, patients, and their fellow Young Investigators. Mentoring Moments were shared amongst the Young Investigators by Expert Judge Mentors Drs. Lecia Sequist, Jessica Donington, Mary Jo Fiddler, John Heymach, Helena Yu, Christine Lovly, Stephen Liu, and Zofia Piotrowska with a Small Groups Breakout where the Young Investigators were able to network and find mentorship with the Expert Judge Mentors. The first day ended with an exciting Trivia Happy Hour hosted by EGFR Resisters' Jill Feldman.



Guest speaker, Chris Draft, former NFL star and founding member of the Chris Draft Family Foundation, kicked off the second day of the Research Summit by reiterating the importance of the collaboration of the patient and patient advocate within clinical research and practice. The Young Investigators, Expert Judge Mentors, and patient advocates convened for the General Session Presentations. Mentoring Moments and Small Group Breakouts followed the General Presentation Session to further establish the connectivity of the Young Researchers with each other as well as the Expert Judge Mentors. The final guest speaker, Dr. David H. Johnson, touched upon the qualities and practices of a successful researcher, where he conveyed vignettes of time management, qualities of a good mentor, and the components of intrinsic and extrinsic success.

The meeting concluded with an awards session, where five top-performing Young Investigators were honored for their exemplary work—the EGFR Resisters Distinguished Young Investigator Grand Prize, 1st Runner-up, 2nd Runner-up, and winners for the two Breakout Sessions.



ABOUT THE EGFR RESISTERS PATIENT ADVOCACY GROUP

Established in 2017 by seven original members—who drew on their experience as patients, survivors, caregivers, and healthcare providers—the EGFR Resisters represent a grassroots, patient-driven community dedicated exclusively to changing *EGFR*-mutated lung cancer into a chronic, manageable disease. With more than 3,700 members from over 90 countries across the globe, the EGFR Resisters have become a well-established and widely-known oncogene driver group that is galvanizing research efforts in meaningful and unique ways, including data gathering efforts such as Project PRIORITY and the EGFR Resisters Research Summit, which is a Young Investigator Forum that brings together established experts with the next generation of lung cancer researchers. CEC Oncology is excited and honored to partner with the EGFR Resisters in organizing and delivering the Summit each year.

 2021 EGFR RESISTERS DISTINGUISHED YOUNG INVESTIGATOR GRAND PRIZE—\$10,000



Elaine Shum, MD

Assistant Professor
NYU Perlmutter Cancer Center
New York, NY

***Lung Cancer Screening in Female Asian Nonsmokers:
Exploring Screening in a High-risk Population***

Dr. Shum is an assistant professor and thoracic medical oncologist at NYU Perlmutter Cancer Center. She graduated from Yale University with a Bachelor's of Science in Biology and attended Stony Brook University School of Medicine for her medical degree. She completed her hematology and oncology fellowship at Montefiore Medical Center/Albert Einstein School of Medicine. At NYU Perlmutter Cancer Center, she sees patients with thoracic malignancies and in the Phase I program. She is the principal investigator of several thoracic oncology and Phase I clinical trials. Her interests include lung cancer in never smokers, lung cancer screening in nonsmokers, new drug development, and targeted therapies for lung cancer.

"Participating in the EGFR RRS was a great experience to connect and network with lung cancer experts and young investigators who are all committed to advancing scientific research for EGFR-mutated lung cancers. This award also has helped to increase awareness of my study and the work that I have been doing."

"I plan to use the grant award to further support the New York Female Asian Nonsmoker Screening Study. We continue to do patient outreach with printed patient materials and virtual presence and will plan to apply the grant award to these supportive costs."

 1ST RUNNER-UP—\$2,500



Laura Petrillo, MD

Physician, Division of Palliative Care
Massachusetts General Hospital
Boston, MA

***Pulling Back the Curtain on Prognostic Communication in the Precision Oncology Era:
Triangulation across Visit Transcripts and Patient, Caregiver, and Clinician Perspectives***

"I was very glad for the networking opportunity with current and rising leaders in lung cancer research and also gained many practical tips for having a productive and fulfilling research career."

"I plan to use the funding on developing a logo and materials for patient retention on our future study of a survivorship/palliative care intervention for patients with recently-diagnosed lung cancer receiving targeted therapy."

 2ND RUNNER-UP—\$1,500



Manish Thiruvalluvan, PhD

Research Fellow
Cedars-Sinai Medical Center
Los Angeles, CA

***Restoring Therapeutic Efficacy of Osimertinib in EGFR-driven NSCLC by Targeting
BMP/Endoglin Signaling***

"Participating in this conference has allowed my lab, a historically prostate cancer focused lab, to have gained large exposure to the field of lung cancer. The connections I made will hopefully help me with future collaborations in lung cancer, as well as allow me to improve my job prospects in the future."

"I will be using the grant to fund RNA sequencing work that I'm currently working on."

 **BREAKOUT SESSION 1 WINNER—\$1,000**



Yin P. (Rex) Hung, MD, PhD

Assistant Pathologist/Assistant Professor of Pathology
Massachusetts General Hospital/Harvard Medical School
Boston, MA

EGFR-mutant Pulmonary Neuroendocrine Tumors: Clinicopathologic and Molecular Characteristics

"It was great meeting diverse expert investigators working on various challenging problems in EGFR-positive lung cancer. The meeting has given me multiple ideas on how to pursue more translational/clinical research efforts on EGFR-positive lung cancers to improve the diagnostics for patients."

"This grant award would be used to support translational cancer research at MGH Pathology."

 **BREAKOUT SESSION 2 WINNER—\$1,000**



Joshua E. Reuss, MD

Assistant Professor of Medicine
Georgetown Lombardi Comprehensive Cancer Center
Washington, DC

A Phase II Open-label Study of Tiragolumab plus Atezolizumab and Bevacizumab in Advanced TKI-refractory, ICB-naïve EGFR-mutated NSCLC

"Participating in the EGFR RRS will have a lasting impact on my professional development, as well as my future clinical and scientific endeavors. The EGFR RRS provided such a rare opportunity to come together with patient advocates, colleagues, and thought leaders in an intimate setting to share research ideas, network, and learn impactful life and career lessons. Critically, what I learned from patient advocates will help to inform my clinical trial design skillset, as to maximize patient inclusion in a fair and equitable way. I was also able to establish new connections with mentors who I plan to collaborate with on further scientific investigation from my trial. Overall, I cannot recommend the EGFR RRS enough. It is an event all aspiring lung cancer providers, patients, and advocates should seek to take part in."

"This generous award will be utilized to perform important correlative scientific analyses for my clinical trial. These analyses will seek to illuminate the immunobiology of EGFR-mutated NSCLC and how immune checkpoint blockade works together with VEGF inhibition to promote clinical benefit in patients with EGFR-mutated NSCLC."



Neel Chudgar, MD
@nchudgar

...

Terrific meeting @EGFRSummit! Thankful to be a part of this and for all the faculty's commitment to career development! #lscm #lcam



Elaine Shum
@ElaineShumMD

...

Replying to @EGFRSummit @nyulangone and 2 others

Thank you so much @EGFRResisters @EGFRSummit! Truly honored for this and humbled to be doing such a study. Great conference and amazing work from all the young investigators at the meeting!!! 😊



Joshua Reuss
@Joshua_Reuss

...

Thank you @EGFRSummit for a truly rewarding and meaningful experience I won't soon forget. the opportunity to learn from amazing advocates incl @jillfeldman4 @ivybelkins Lindi Campbell, great mentors and colleagues is unmatched. I encourage all to attend @EGFRSummit next yr!!!



Lecia V. Sequist, MD, MPH
Activity Chair | Planning Committee
Landry Family Professor of Medicine
Harvard Medical School
Director of Center for Innovation
in Early Cancer Detection
Massachusetts General Hospital
Boston, MA



Stephen V. Liu, MD
Thoracic Medical Oncologist
Associate Professor of Medicine
Georgetown University
Director of Thoracic Oncology
Head of Developmental Therapeutics
Georgetown University Lombardi Comprehensive
Cancer Center
Washington, DC



Jessica Donington, MD, MSCR
Planning Committee
Professor of Surgery
Chief, Section of Thoracic Surgery
The University of Chicago Medicine
Chicago, IL



Christine M. Lovly, MD, PhD
Associate Professor of Medicine, Division of
Hematology-Oncology
Ingram Associate Professor of Cancer Research
Co-Leader, Translational Research and
Interventional Oncology Program
Group Leader, Basic and Translational Research
Vanderbilt University Medical Center
Vanderbilt Ingram Cancer Center
Nashville, TN




Mary Jo Fidler, MD
Associate Professor of Medicine
Section Chief of Medical Oncology
Division of Hematology, Oncology, and Cell
Therapy
Rush University Medical Center
Chicago, IL



Zofia Piotrowska, MD, MHS
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, MA



John V. Heymach, MD, PhD
Professor and Chair
David Bruton, Jr. Chair in Cancer Research
Department of Thoracic/Head and Neck
Medical Oncology
MD Anderson Cancer Center
Houston, TX



Helena A. Yu, MD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, NY



Ivy Elkins, MBA
 Founding Member, EGFR Resisters
 EGFR+ NSCLC since 2014
 Evanston, IL



Jill Feldman, MA
 Founding Member, EGFR Resisters
 EGFR+ NSCLC since 2009
 Deerfield, IL



Lindi Campbell
 Founder, Breath of Hope Kentucky, Inc.
 Lexington, KY



Being able to meet and get to know Jill, Ivy, and Lindi really allowed me to gain a different perspective and find meaning in the work and research that I do.





Jacqueline Aredo, MD, MS

Resident Physician
University of California–San Francisco
San Francisco, CA

Uncovering Molecular Drivers of Neuroendocrine Plasticity in Patients with Small Cell Lung Cancer Transformation at Single-cell Level



Sumit Mukherjee, PhD

Postdoctoral Research Fellow
Albert Einstein College of Medicine
Bronx, NY

ART1-induced Mono-ADP-ribosylation Induces Immune Suppression in EGFR-mutated Lung Cancer



Neel Chudgar, MD

Assistant Professor, Cardiothoracic and Vascular Surgery | Montefiore Medical Center
Albert Einstein College of Medicine | Bronx, NY

Thinking Outside the Box for Locally-advanced Stage IIIB EGFR-mutated Lung Cancer: A Case Report



Laura Petrillo, MD

Physician, Division of Palliative Care
Massachusetts General Hospital
Boston, MA

Pulling Back the Curtain on Prognostic Communication in the Precision Oncology Era: Triangulation across Visit Transcripts and Patient, Caregiver, and Clinician Perspectives



Alissa Cooper, MD

Clinical Fellow in Hematology/Oncology
Massachusetts General Hospital
Boston, MA

Resistance to Third-generation EGFR TKIs: an Update on Mechanisms and Management Strategies



Sawsan Rashdan, MD

Assistant Professor
UT Southwestern Medical Center
Dallas, Texas


Osimertinib and Consolidation Stereotactic Ablative Radiotherapy (SABR) in Newly-diagnosed Advanced EGFR-mutant Non-small Cell Lung Cancer with Oligometastases: A Phase II Clinical Trial



Ines Pulido Endrino, PhD

Postdoctoral Research Associate
University of Illinois–Chicago
Chicago, IL

NNMT Drives Mesenchymal-like Phenotype and Generates Metabolic Vulnerabilities in EGFR-mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors



Joshua E. Reuss, MD

Assistant Professor of Medicine
Georgetown Lombardi Comprehensive Cancer Center | Washington, DC

A Phase II Open-label Study of Tiragolumab plus Atezolizumab and Bevacizumab in Advanced TKI-refractory, ICB-naïve EGFR-mutated NSCLC



Michael J. Grant, MD

Hematology/Medical Oncology Clinical Fellow
Yale University
New Haven, CT

Investigating the Efficacy of Osimertinib in Patients with Tumors Harboring the Uncommon EGFR Exon 19 Deletion, L747_A750delinsP



Elaine Shum, MD

Assistant Professor
NYU Perlmutter Cancer Center
New York, NY

Lung Cancer Screening in Female Asian Nonsmokers: Exploring Screening in a High-risk Population



Yin P. (Rex) Hung, MD, PhD

Assistant Pathologist/Assistant Professor of Pathology
Massachusetts General Hospital/Harvard Medical School | Boston, MA

EGFR-mutant Pulmonary Neuroendocrine Tumors: Clinicopathologic and Molecular Characteristics



Jane Sze Yin Sui, MB, BCh, BAO

Fellow
Memorial Sloan Kettering Cancer Center
New York, NY

A Phase II Study of Afatinib with Ramucirumab in Untreated Uncommon EGFR-mutant Metastatic Non-small Cell Lung Cancer

 2021 EGFR RESISTERS RESEARCH SUMMIT ATTENDEES (CONTINUED)



Manish Thiruvalluvan, PhD
 Research Fellow
 Cedars-Sinai Medical Center
 Los Angeles, CA
Restoring Therapeutic Efficacy of Osimertinib in EGFR-driven NSCLC by Targeting BMP/Endoglin Signaling



Karen M. Yun, MD
 Hematology-Oncology Fellow
 University of California–San Diego
 San Diego, CA
ART1-induced Mono-ADP-ribosylation Induces Immune Suppression in EGFR-mutated Lung Cancer





Hollis Viray, MD
 Hematology Oncology Fellow
 Beth Israel Deaconess Medical Center
 Boston, MA
A Real-world Study of Patient Characteristics and Clinical Outcomes in EGFR-mutated Lung Cancer Treated with First-line Osimertinib



Nicole Yun, MD
 Resident Physician
 Rush University Medical Center
 Chicago, IL
RNA Sequencing to Characterize Pathways in EGFR-mutated Non-small Cell Lung Cancer



Mitchell von Itzstein, MD
 Oncology Fellow
 UT Southwestern
 Dallas, TX
Efficacy of Osimertinib in a Patient with a Rare EGFR L747P Mutation



RESEARCH PUBLICATIONS

Padda SK, **Aredo JV**, Vali S, et al. Computational biological modeling identifies PD-(L)1 immunotherapy sensitivity among molecular subgroups of *KRAS*-mutated non-small-cell lung cancer. *JCO Precis Oncol*. 2021;5:153–162.

Aredo JV, Wakelee HA, Neal JW, Padda SK. Afatinib after progression on osimertinib in EGFR-mutated non-small cell lung cancer. *Cancer Treat Res Commun*. 2021;30:100497.

Choi E, Luo SJ, **Aredo JV**, et al. The survival impact of second primary lung cancer in patients with lung cancer. *J Natl Cancer Inst*. December 10, 2021. Epub ahead of print.

Aredo JV, Hellyer JA, Neal JW, Wakelee HA. Consolidation durvalumab should not be administered to patients with stage iii EGFR-mutant NSCLC. *J Thorac Oncol*. 2021;16(12):1994–1998

Shah MP, **Aredo JV**, Padda SK, et al. EGFR exon 20 insertion NSCLC and response to platinum-based chemotherapy. *Clin Lung Cancer*. 2022;23(2):e148–e153.

Choi E, Sanyal N, ... **Aredo JV**, et al. Development and validation of a risk prediction model for second primary lung cancer. *J Natl Cancer Inst*. 2022;114(1):87–96.

Cooper AJ, Gainor JF. Human epidermal growth factor receptor 2-mutant non-small-cell lung cancer: continued progress but challenges remain. *J Clin Oncol*. 2022;40(7):693–697.

Cooper AJ, Sequist LV, Johnson TW, Lin JJ. LTK fusions: a new target emerges in non-small cell lung cancer. *Cancer Cell*. 2022;40(1):23–25.

Martin RL 3rd, **Grant MJ**, Kimani S, et al. Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: experiential lessons learned from a novel trainee-led multidisciplinary virtual learning platform. *JCO Oncol Pract*. 2022;18(1):e36–e46.

Temel JS, **Petrillo LA**, Greer JA. Patient-centered palliative care for patients with advanced lung cancer. *J Clin Oncol*. 2022;40(6):626–634.

Reuss JE, Gosa L, Liu SV. Antibody-drug conjugates in lung cancer: state of the current therapeutic landscape and future developments. *Clin Lung Cancer*. 2021;22(6):483–499.

Connolly SP, McGrath J, **Sui J**, Muldoon EG. Rare, disseminated Kaposi sarcoma in advanced HIV with high-burden pulmonary and skeletal involvement. *BMJ Case Rep*. 2021;14(12):e245448.

Sui JSY, Finn SP, Gray SG. Detection of MET exon 14 skipping alterations in lung cancer clinical samples using a PCR-based approach. *Methods Mol Biol*. 2021;2279:145–155.

O'Reilly D, Carroll H, ... **Sui J**, et al. Virtual oncology clinics during the COVID-19 pandemic. *Ir J Med Sci*. 2021;190(4):1295–1301.

Kobayashi IS, **Viray H**, Rangachari D, et al. EGFR-D770>GY and other rare EGFR exon 20 insertion mutations with a G770 equivalence are sensitive to dacomitinib or afatinib and responsive to EGFR exon 20 insertion mutant-active inhibitors in preclinical models and clinical scenarios. *Cells*. 2021;10(12):3561.

von Itzstein MS, Gonugunta AS, Wang Y, et al. Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors. *Cancer Immunol Immunother*. January 24, 2022. Epub ahead of print.

Hsiehchen D, Naqash AR, Espinoza M, **von Itzstein MS**, et al. Association between immune-related adverse event timing and treatment outcomes. *Oncoimmunology*. 2022;11(1):2017162.

Gonugunta AS, **von Itzstein MS**, ... **Rashdan S**, et al. Humoral and cellular correlates of a novel immune-related adverse event and its treatment. *J Immunother Cancer*. 2021;9(12):e003585.


Yun NK, Slostad JA, Naqib A, et al. Histologic discordance between primary tumor and nodal metastasis in breast cancer: solving a clinical conundrum in the era of genomics. *Oncologist*. 2021;26(12):1000–1005.




15 INSTITUTIONS REPRESENTED

- Beth Israel Deaconess Medical Center (Boston, MA)
- Cedars-Sinai Medical Center (Los Angeles, CA)
- City of Hope (Los Angeles, CA)
- Georgetown Lombardi Comprehensive Cancer Center (Washington, DC)
- Mass General Hospital/Harvard Medical School (Boston, MA)
- Memorial Sloan Kettering Cancer Center (New York, NY)
- Montefiore Medical Center at the Albert Einstein College of Medicine (Bronx, NY)
- NYU Perlmutter Cancer Center (New York, NY)
- Rush University Medical Center (Chicago, IL)
- Stanford (Palo Alto, CA)
- University of California–San Diego (San Diego, CA)
- University of California–San Francisco (San Francisco, CA)
- University of Illinois–Chicago (Chicago, IL)
- UT Southwestern Medical Center (Dallas, TX)
- Yale University (New Haven, CT)


PARTICIPANT GENDER



PARTICIPANT CATEGORY



PARTICIPANT DIVERSITY






Stephanie Roberson Barnard
ListenWritePresent, LLC
Greensboro, NC

Professional Skills Enhancement Workshop

To augment the professional development aspects of the EGFR Resistors Research Summit, 2021 participants had the opportunity to receive individual coaching sessions by expert coach, Stephanie Barnard, from ListenWritePresent. Young investigators who participated in the one-on-one pre-program coaching sessions received expert advice and critique of their presentation and public speaking skills, and were given a copy of the book *Listen. Write. Present.*, which was written by the ListenWritePresent team. In addition, the expert coach provided participants with tips for effective navigation of expert Q&A and research defense.



2021 EGFR Resistors Research Summit attendees found the **ListenWritePresent Professional Skills Enhancement Workshop** to be an extremely valuable component of the EGFR Summit curriculum, ranking the coaching sessions with a mean score of **3.92** on a 4.0 scale.

What Participants Value Most


- "The scientific sessions and hearing the judge feedback and questions. The didactic mentoring moments were also great."*
- "The small-group breakout sessions. Felt you could really ask questions one-on-one and get valuable feedback on any topic."*
- "Speaking with the faculty mentors and patient advocates. The presentation coach also was great."*
- "Hearing from other academic oncologists and their advice on how to balance work and life"*

Mentoring Moments and Small-group Networking Sessions

- "Excellent panel of mentors. Very approachable, helpful, and great insight that covered all aspects of academia."*
- "Diverse array of faculty all with complementary advice and help to offer. Everyone was genuinely interested."*
- "Very much appreciate the opportunity to virtually meet and learn from these experienced clinicians and researchers!"*

How Attending the Summit Will Impact Young Investigators' Careers

- "The networking helps to potentially broaden my research to other institutions."*
- "The feedback will help with development of a manuscript from these data. I also learned a lot about current EGFR research and gained valuable career tips, such as how to use time wisely and where to focus my efforts."*
- "Participating helped me to build my professional network, also learned best research practices from lung cancer experts."*
- "Learning more about the important research/clinical questions that matter to patients."*




Unusual (Again!) but Not Uninspiring!

"Wonderful conference; wish it were in person, but for a virtual conference it was really well done and was more personal than other virtual conferences I have been on. Great speakers and sessions."

"Extremely well-organized and executed virtual meeting."

"This meeting was very well run and so generous - the most thoughtful touches, from the GrubHub to the sweatshirt and gifts. And the best part was the dedication of the mentors and the advocates to the investigators' career development and success- made it a very meaningful meeting."

"Thank you for organizing this fabulous meeting. It exceeds my expectations on how much one learns from this community, and this meeting certainly motivates me to do better research."




Technology Made It Possible

"One of the best and most seamless virtual conferences I have attended."


"The kit provided and the sessions before the meeting were very helpful."

"It was great!"



Why Spend Time on Social Media?

- It is here to stay
- To learn
- To teach
 - Explain your research
 - Provide an informed voice
 - Highlight important work
 - Journals have turned to social media (from "pull" to "push")



WATCH FOR NEWS ON THE 2022 EGFR SUMMIT
4th Annual EGFR Resisters Research Summit
November 17-19, 2022

Follow us on Twitter @EGFRSummit or visit ceconcepts.com/egfrsummit22